<DOC>
	<DOCNO>NCT02663024</DOCNO>
	<brief_summary>This study evaluate efficacy safety three dos GC1111 patient Hunter Syndrome . Participants randomize one three dos GC1111 comparator .</brief_summary>
	<brief_title>Study Idursulfase-beta ( GC1111 ) Hunter Syndrome</brief_title>
	<detailed_description>This randomize , double-blind , active-controlled , dose-ranging study , patient receive one three dos GC1111 ( 0.5 mg/kg , 1.0 mg/kg , 1.5 mg/kg ) ELAPRASE 0.5 mg/kg . Approximately 20 patient administrated study drug every week iv infusion 24 week . Efficacy GC1111 evaluate Six-Minute Walk Test ( 6MWT ) , urine Glycosaminoglycans ( uGAG ) , liver spleen volume , percent predict Forced Vital Capacity ( FVC ) , cardiac size function . Also immunogenicity , Pharmacokinetics ( PK ) safety evaluate .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Male patient 5 35 year age Informed consent form sign Patients diagnosed hunter syndrome Previously untreated enzyme replacement therapy History tracheostomy , bone marrow transplant , cord blood transplant Treatment another investigational product within 30 day prior start study drug Known hypersensitivity ingredient study drug Patient severe hunter syndrome perform 6MWT Female patient</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>